Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Net Income towards Common Stockholders: 2017-2024

Historic Net Income towards Common Stockholders for Kiniksa Pharmaceuticals International (KNSA) over the last 8 years, with Dec 2024 value amounting to -$43.2 million.

  • Kiniksa Pharmaceuticals International's Net Income towards Common Stockholders rose 245.24% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year increase of 142.99%. This contributed to the annual value of -$43.2 million for FY2024, which is 28.48% up from last year.
  • According to the latest figures from FY2024, Kiniksa Pharmaceuticals International's Net Income towards Common Stockholders is -$43.2 million, which was up 28.48% from -$60.4 million recorded in FY2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Net Income towards Common Stockholders peaked at $267.4 million during FY2022, and registered a low of -$167.1 million during FY2020.
  • Its 3-year average for Net Income towards Common Stockholders is $54.6 million, with a median of -$43.2 million in 2024.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Net Income towards Common Stockholders spiked by 261.42% in 2022, and later crashed by 122.58% in 2023.
  • Kiniksa Pharmaceuticals International's Net Income towards Common Stockholders (Yearly) stood at -$167.1 million in 2020, then grew by 0.88% to -$165.7 million in 2021, then soared by 261.42% to $267.4 million in 2022, then tumbled by 122.58% to -$60.4 million in 2023, then grew by 28.48% to -$43.2 million in 2024.